BACKGROUND: t(8;21)(q22;q22), found in acute myeloid leukemia (AML) and occasionally in myelodysplasia (MDS), results in the fusion of the AML1 gene on 22q22 to the ETO gene on 8q22, generating a chimeric AML1/ETO transcript, which is a molecular marker of the translocation. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR), with two pairs of nested AML1 and ETO primers, was used to amplify the AML1/ETO fusion transcript. The Kasumi-1 cell line was used as a positive control. RESULTS: RT-PCR has a sensitivity of 0.0001% (10(-6)), corresponding to detection of 0.5 picograms of leukemic RNA in the presence of 0.5 micrograms of normal RNA. Using this approach, patients with t(8;21) (three patients with de novo AML, one with therapy-related AML, and one patient with myelodysplasia) yielded the same 222 base pair PCR product, suggesting that the breakpoints occurred at the same AML1 and ETO introns as previously reported. Three patients were still PCR-positive when in complete remission after chemotherapy and two experienced relapse. However, in another three patients with t(8;21) who were in remission for 2 months, 2 years, and 3 1/2 years, respectively, PCR was negative. CONCLUSION: RT-PCR is a sensitive method of detection of t(8;21), and is useful in the monitoring of minimal residual leukemia. As the junction of AML1/ETO appears to be constant, RT-PCR may offer a quick and accurate diagnosis of t(8;21).
BACKGROUND: t(8;21)(q22;q22), found in acute myeloid leukemia (AML) and occasionally in myelodysplasia (MDS), results in the fusion of the AML1 gene on 22q22 to the ETO gene on 8q22, generating a chimeric AML1/ETO transcript, which is a molecular marker of the translocation. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR), with two pairs of nested AML1 and ETO primers, was used to amplify the AML1/ETO fusion transcript. The Kasumi-1 cell line was used as a positive control. RESULTS: RT-PCR has a sensitivity of 0.0001% (10(-6)), corresponding to detection of 0.5 picograms of leukemic RNA in the presence of 0.5 micrograms of normal RNA. Using this approach, patients with t(8;21) (three patients with de novo AML, one with therapy-related AML, and one patient with myelodysplasia) yielded the same 222 base pair PCR product, suggesting that the breakpoints occurred at the same AML1 and ETO introns as previously reported. Three patients were still PCR-positive when in complete remission after chemotherapy and two experienced relapse. However, in another three patients with t(8;21) who were in remission for 2 months, 2 years, and 3 1/2 years, respectively, PCR was negative. CONCLUSION: RT-PCR is a sensitive method of detection of t(8;21), and is useful in the monitoring of minimal residual leukemia. As the junction of AML1/ETO appears to be constant, RT-PCR may offer a quick and accurate diagnosis of t(8;21).